ANTIMICROBIAL AGENT’S UTILIZATION AND COST PATTERN IN MEDICAL INTENSIVE CARE UNIT OF A TERTIARY CARE HOSPITAL
DOI:
https://doi.org/10.22159/ijpps.2021v13i8.41338Keywords:
DDD (Defined daily dose), ATC (Anatomical therapeutic chemical), Antimicrobial utilization, ICU (Intensive care unit)Abstract
Objective: The objective of this study was to evaluate the utilization and cost pattern of AMAs (Antimicrobial Agents) in the Medical ICU of a tertiary care teaching hospital, and to determine the predictor of antimicrobial number per day.
Methods: A prospective cross-sectional study was carried out and a total of 101 patients were studied. The drugs were classified into different groups according to the World Health Organization’s ATC (Anatomical Therapeutic Chemical) Classification System.
Results: The mean [95% confidence interval (CI)] duration of ICU stay was 7.11 (5.70-8.52) days and the mortality rate in the ICU was 42.6%. The AMAs DDD (Defined Daily Dose) per 100 patient days and number of AMAs per prescription were 296.64 and 2.65, respectively. Piperacillin-tazobactam was the most commonly utilized AMAs followed by metronidazole, meropenem, fluconazole, and colistin. The mean number [95% CI] of AMAs, DDD, and cost (INR) per patient were 18.82 (14.05-23.59), 21.09 (15.36-26.81) and 25,827 (18,716-32,939) respectively. The AMAs constituted 88.53% of the total treatment cost. Meropenem was the most costly AMA (32.10% of the total AMAs cost) followed by imipenem-cilastatin (20.50%), colistin (14.65%), piperacillin-tazobactam (8.40%), and clindamycin (4.47%). The independent predictor for the antimicrobial number per day was acute physiology and chronic health evaluation II (APACHE-II) score at admission and nosocomial infections.
Conclusion: The AMAs, DDD per 100 patient days, and number per prescription were higher. This leads to a higher cost of AMAs per patient and the AMAs cost out of the total cost as compared to previous studies. We suggest, there is a need to formulate and implement an antimicrobial restriction policy.
Downloads
References
Methodology WHOIWG for DS, Methodology WHOCC for DS, Services WHOCC for DUR and CP. Introduction to drug utilization research [Internet]. Geneva PP-Geneva: World Health Organization; Available from https://apps. who. int/iris/handle/10665/42627. Accessed: 2020-09-07.
Reder BL, Nielsen SL, Magnussen P, Engquist A, Frimodt-Møller N. Antibiotic usage in an intensive care unit in a Danish university hospital. J Antimicrob Chemother. 1993;32:633–42.
Esposito S, Leone S. Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist. International journal of antimicrobial agents. 2007;29:494-500.
Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol. 2007;45:3352–9.
Weber RJ, Kane SL, Oriolo VA, Saul M, Skledar SJ, Dasta JF. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med. 2003;31:S17-24.
MD MHK, Ward S. The Influence of Mini-BAL Cultures on Patient Outcomes: Implications for the Antibiotic Management of Ventilator-Associated Pneumonia. Chest [Internet]. 1998;113:412–20.
Global Risks Report 2011. World Economic Forum. Available from: https://www. weforum. org/reports/global-risks-report-2011. Accessed: 2020-09-07
Paterson DL, Rogers BA. How soon is now? The an urgent need for randomized, controlled trials evaluating the treatment of multidrug-resistant bacterial infection. Clin Infect Dis. 2010;51:1245–7.
Archibald L, Phillips L, Monnet D, McGowan JE, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis. 1997;24:211–5.
WHO ATC/DDD Index 2016. Available from: http//www. whocc. no/atc_ddd_index./. Accessed: 2016-09-12.
Brunton L, Chamber B, Knollman B, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw Hill; 2011. p. 1365 81.
Shankar PR, Upadhyay DK, Subish P, Bhandari RB, Das B. Drug utilisation among older inpatients in a teaching hospital in western Nepal. Singapore Med J. 2010;51:28–34.
Patel MK, Barvaliya MJ, Patel TK TC. Drug utilization pattern in critical care unit in a tertiary care teaching hospital in India. Int J Crit Illn Inj Sci. 2013;3:250.
Curcio DJ, Curcio D, Alí A, Duarte A, Defilippi Pauta A, Guerrón AFE, et al. Antibiotic prescription in intensive care units in Latin America. Rev Argent Microbiol. 2011;43:203–11.
Anand N, Nagendra Nayak IM, Advaitha M V, Thaikattil NJ, Kantanavar KA, Anand S. Antimicrobial agents’ utilization and cost pattern in an Intensive Care Unit of a Teaching Hospital in South India. Indian J Crit care Med peer-reviewed, Off Publ Indian Soc Crit Care Med. 2016;20:274–9.
Smythe MA, Melendy SU, Jahns BR, Dmuchowski CA. An exploratory analysis of medication utilization in a medical intensive care unit. Critical care medicine. 1993;21:1319-23.
Tavallaee M, Fahimi F, Kiani S. Drug-use patterns in an intensive care unit of a hospital in Iran: an observational prospective study. Int J Pharm Pract. 2010 Dec; 18(6):370–6.
Williams A, Mathai AS, Phillips AS. Antibiotic prescription patterns at admission into a tertiary level intensive care unit in Northern India. J Pharm Bioallied Sci. 2011;3:531–6.
Paul N, Santhosh Kumar V. A comparative study on drug use of antimicrobial agents in medical and surgical intensive care units of a tertiary care hospital. Asian J Pharm Clin Res. 2018;11:310–3.
Bitterman R, Hussein K, Leibovici L, Carmeli Y, Paul M. Systematic review of antibiotic consumption in acute care hospitals. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22:561. e7-561. e19.
Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997:A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1999;27:279–84.
Adeli O, Markazi Moghaddam N, Hamidi Farahani R, Zargar Balaye Jame S. Antibiotics use patterns in intensive care units of five hospitals in Tehran during 2011-2012. Journal of Archives in Military Medicine. 2015;3:e27862.
Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI). Infection. 2003;31:208–15.
Inan D, Saba R, Gunseren F, Ongut G, Turhan O, Yalcin AN, et al. Daily antibiotic cost of nosocomial infections in a Turkish university hospital. BMC Infect Dis. 2005;5:1–6.
Amit GS. Drug Use Evaluation Study in a Tertiary Care Corporate Hospital with Special Reference to Use of Antibiotics in ICU Department. Int J Adv Pharmacy, Biol Chem. 2013;2:179–89.
Mangrulkar VS, Mangrulkar S, Khair P PA. Antibiotic Use in the Intensive Care Unit. J Assoc Physicians India. 2012;60:15–8.
Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, et al. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents. 2008;31:161–5.
John LJ, Devi P, John J, Guido S. Drug utilization study of antimicrobial agents in medical intensive care unit of a tertiary care hospital. Asian J Pharm Clin Res. 2011;4:81–4.
Published
How to Cite
Issue
Section
Copyright (c) 2021 Dr. Sartaj Hussain Sartaj, Dr. Suraj Singh Yadav suraj, Dr. Kamal Kumar Sawlani Kamal, Dr. Kauser Usman Kauser, Dr. Sanjay Khattri sanjay
This work is licensed under a Creative Commons Attribution 4.0 International License.
